Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
نویسندگان
چکیده
BACKGROUND Cognitive dysfunction occurs at the earliest stages of multiple sclerosis (MS), including the stage of clinically isolated syndrome (CIS). METHODS We evaluated the impact of interferon beta-1b (IFNβ-1b) 250 µg on cognitive performance during the CIS stage in the BENEFITstudy. Cognition was assessed by Paced Auditory Serial Addition Test-3" (PASAT-3") scores. RESULTS Improvement in PASAT-3" score from baseline to year two was greater for IFNβ-1b treatment than placebo in patients not reaching clinically definite MS (CDMS) by year two. The treatment effect was maintained at year five and was statistically significant. CONCLUSIONS To conclude, early IFNβ-1b treatment had a sustained positive effect on PASAT-3" score over the 5-year BENEFIT study.
منابع مشابه
Effect of the Sera of Patients with Multiple Sclerosis on Apoptosis and Nitric Oxide Production of Endothelial Cells
Background & Aims: Multiple sclerosis (MS) is one of the chronic autoimmune diseases of the central nervous system with unknown etiology. The present study aimed to investigate the apoptosis and nitric oxide (NO) production of endothelial cells treated with serum of patients with MS and response to interferon beta (IFN- ) therapy. Methods: Human umbilical vein endothelial cells were treated wit...
متن کاملTreatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
OBJECTIVE To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple sclerosis (MS) (clinically isolated syndrome). METHODS We conducted a multicenter, randomized, double-blind, placebo-controlled trial. Patients with a first clinical demyelinating event and at least two clinically silent brain MR...
متن کاملLong-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
OBJECTIVE To examine the long-term impact of early treatment initiation of interferon beta-1b (IFNB1b, Betaferon/Betaseron) in patients with a first event suggestive of multiple sclerosis (MS). METHODS In the original placebo-controlled phase of BENEFIT, patients were randomised to IFNB1b 250 μg or placebo subcutaneously every other day. After 2 years or diagnosis of clinically definite MS (C...
متن کاملMagnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
BACKGROUND In the Betaseron/Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) study, interferon beta-1b delayed conversion to multiple sclerosis in patients with a first clinical event and at least 2 clinically silent brain magnetic resonance imaging (MRI) lesions. OBJECTIVE To examine detailed MRI findings from the first 2 years of this trial. DESIGN Double-bli...
متن کاملتجزیه و تحلیل فیلوژنتیکی و آنالیز In Silico پروتئین اینترفرون بتا 1 بی
Background and purpose: Interferon beta-1b recombinant protein is used for reducing the relapse rate and treatment in patients with Multiple sclerosis (MS). In this study, phylogenetic and in silico analysis of interferon beta-1b were conducted by servers and bioinformatics tools to predict its structural potential. Materials and methods: Physiological and physico-chemical characteristics of...
متن کامل